From left: Samir and Sudhir Mehta.
Mexy Xavier/Forbes India
This story is part of Forbes’ coverage of India’s Richest 2025. See the full list here.
Brothers Sudhir and Samir Mehta are riding the momentum of India’s ambition to become the world’s pharmacy. In June, Torrent Pharmaceuticals, the flagship of their Ahmedabad-based Torrent Group, agreed to buy U.S. private equity giant KKR’s 46% stake in rival JB Chemicals & Pharmaceuticals for 119 billion rupees ($1.3 billion), valuing the firm at $3 billion. This was followed by a mandatory open offer to buy an additional 26% stake for around 68 billion rupees, setting the stage to merge Mumbai-based JB Pharma with Torrent.
According to a statement from Samir, who chairs both the pharma business and the larger group, Torrent Pharma’s top and bottom lines will get a boost from JB Pharma’s fast-growing India business and international footprint. In the year to March 31, Torrent Pharma logged a modest 7% revenue rise to 115.2 billion rupees, compared with a 12% sales jump at JB Pharma to 39.2 billion rupees.
Torrent Group, which also has interests in energy, was founded in 1959 by the brothers’ late father, Uttambhai Nathalal Mehta. The siblings moved up a notch to No. 15 in the ranking despite a 14% decline in their combined fortune to $14.1 billion.